On December 16, 2016, SeekingAlpha.com published a report revealing how the "FDA is actively moving to 'down classify' BGS from Class III to Class II, allowing cheap competition to flood in, stealing revenues and crushing margins." The report goes on to state that "as of October 1st, 2016 (about 10 weeks ago) the FDA just transferred the BGS down classification process to the specific department responsible for handling the down classification (the department of Orthopedics)." Following this news, Orthofix stock dropped harshly during intraday trading on December 16, 2016.
If you are aware of any facts relating to this investigation, or purchased Orthofix shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/ofix. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | email@example.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-orthofix-international-nv-ofix-300379955.html
SOURCE Bronstein, Gewirtz & Grossman, LLC